Drug intelligence / Profile preview

clindamycin

Development stage
Approved
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral, Intravenous, Intramuscular, Topical, Intravaginal
01

Overview

Clindamycin is a semi-synthetic lincosamide antibiotic used to treat a variety of serious infections caused by susceptible microorganisms, including anaerobic bacteria and certain gram-positive cocci such as staphylococci and streptococci. It is also used topically for acne vulgaris. Clindamycin works by inhibiting bacterial protein synthesis through binding to the 23S RNA of the 50S subunit of the bacterial ribosome, thereby impeding ribosomal assembly and translation processes. This action results in bacteriostatic effects but can be bactericidal depending on concentration and organism. Clindamycin was developed by chemically modifying lincomycin, which was originally isolated from Streptomyces lincolnensis. It is indicated for infections such as lower respiratory tract infections (including pneumonia), skin and soft tissue infections, bone and joint infections (including osteomyelitis), intra-abdominal infections (such as peritonitis), gynecological infections (such as endometritis), septicemia, and severe acne[1][2][3][5][8].

Brand names
CleocinCleocin Pediatric
Other names
clindamycin phosphateClindaMax VaginalClindagelCleocin T
02

Targets

Bacterial 50S ribosomal subunit

Beyond the preview

Go deeper on clindamycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on clindamycin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call